Recommendation and upside:
We are initiating coverage on Sartorius Stedim Biotech (SSB; market cap. of c.€5.3bn and a free float of c.26%) with an “Add” recommendation and a target price of €61.7 per share (c.7% upside). SSB is one of the top five players in the high growth €5-6bn oligopolistic bioprocessing industry (the top five players together control >80% of the total market) with a market share of 15-20%. The industry presents robust growth opportunities and is expected to grow at 9-10% p ....
07 Feb 2017
Initiating coverage on Sartorius Stedim Biotech.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Initiating coverage on Sartorius Stedim Biotech.
Sartorius Stedim Biotech SA (0RG8:LON) | 0 0 0.0%
- Published:
07 Feb 2017 -
Author:
Jyoti Prakash -
Pages:
43
Recommendation and upside:
We are initiating coverage on Sartorius Stedim Biotech (SSB; market cap. of c.€5.3bn and a free float of c.26%) with an “Add” recommendation and a target price of €61.7 per share (c.7% upside). SSB is one of the top five players in the high growth €5-6bn oligopolistic bioprocessing industry (the top five players together control >80% of the total market) with a market share of 15-20%. The industry presents robust growth opportunities and is expected to grow at 9-10% p ....